ReviewBMJ neurology open2025
Understanding the progression of Parkinson's disease: a review.
Review in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Dark Matter of Levodopa Pharmacodynamics.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Long-Duration Response to Levodopa in the PPMI-Cohort.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Wearable sensors for monitoring drug pharmacokinetics in patients with Parkinson's disease.Scientific reports · 2026Article
- Integrated PET/MRI for the evaluation of gray matter atrophy and metabolic changes in idiopathic Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Faith, fasting, and well-being: Emirates Neurology Society consensus guidelines on safe Ramadan fasting in Parkinson's disease.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the long term, Parkinson's disease (PD) appears to progress, in a linear fashion, at an annual rate of about 2% of the maximum motor disability score. This figure aligns quite well with pathological research on the rate that substantia nigra dopaminergic neurons are lost. An unexpected finding from cohort studies and clinical trials is that progression is twice as fast in prodromal PD, leading up to clinical diagnosis, and in recently diagnosed PD prior to the commencement of dopaminergic therapy. Levodopa initiation reduces motor disability by 40% of the pretreatment level. This benefit is composed of the short duration response, which is easily measured as the difference between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.